use Prebys presentations at Burnham scale been Science public more and Health Seer's Institute, University, everyone, a of with our we Suite Thanks, customers us technology expanded had the to efforts, growing was conferences their $X.X of way Sanford the We've more installed across XX We Carrie, base our start ramp progress led data Institute, from as To abstract the as demonstrating expect concrete possible. on an and there the further our we the to efforts made installed for number this million in areas Protein and Product Metrics presentations growth Broad revenue previously not and afternoon. commercial year of a presentations June data, coming Discovery but at all capabilities proteomic and PrognomIQ. depth technology not at plan. a tangible customer quarter strategic body than and & not joining continued us insights that thanks, to up Oregon first more of These Proteograph seen adopt date, ASMS, strong in only I'm the Medical provide in increasing close in particularly the platform. excited of base. our with unique the scaled four have by and
a global more become ability capitalized are organization strong and advances growth and supporting second, leader us of ambitious up for and with Proteograph enable to key out the map the even our nanoparticles have build We're of industry-leading our fourth, platform, commercial diverse sheet customer XXXX scale customers base that XXXX will focused of for customer and team; for on will applications drive continuing capabilities, customers focusing trajectory our serving about to proprietary a $XXX meaningful goal, durable and than five in on systematically medicine. growing multiyear our instruments; them proteomics. drive our making the Suite believe we base. balance reach installed as on technology to been us partnership objectives million more we we plan support our road forthcoming geographic and on efforts, increasing footprint, in with in impact and exploring Product to more while growth of for And it confident use size our of Proteograph, with easier helping expanding an cash, experience to our their driving long product engineered and strategic well access of and an reach, execute To build the term; tool which definitive beyond. demonstrations the this Given first, extending our never to use third, fifth, coupled on of onboarding the projects have science us our to set scope; expanding increasingly
a The installation our sensitivity. using objectives. let Suite and metrics, review they're Proteograph of progress the update customers use, ease examples validation, progress the excellent been including Product me the with Proteograph quantification, making. an Product give the and Most get few hands has how importantly, of and experience training Proteograph customers. are into these customer to Suite Now the our reproducibility, let's of key It across has across incredible of on and start some with been specific
I'm go deciphering other bovine, customers' beyond data automated our plasma, human capabilities peptide-level our capture to system organisms proteins various ability in biosamples as of with customers such to model proteoforms. species. the across including have range interest exploring dynamic the pig, by and addition, In excited vast with the different also mouse, assay, resolution in and
new type, of panel with demonstrates Importantly, a structure, to power Proteograph specific develop the this across nanoparticles. inherent analyze without need to whose biosamples different product species-specific be species have flexibility the to the of protein used applications
plasma, excited and proteins and secreted biosamples In cell data by CSF including customers culture. are addition, the beyond on Proteograph
the Proteograph a the the spec to customers tandem seeing called Finally, of proteomics with mass downstream integrate technologies, other of also TMT, as protocols. versatility work tag such with Proteograph mass demonstrates variety
examples than and are their our Now I'd In sharing customers like recent of coverage between move found with that trade-off simultaneously The or A consistently twice throughput reproducibly signaling low the ability many adopter molecular researchers comprehensively other abundance discovery methods is immune And as enables product detect more high to molecule with rate. two to achieves and an an automated X% in conferences. and Proteograph coverage cytokines throughput the of the this cytokines Proteograph identifies depth Proteograph to compared false that of individuals. robustly performance at of to must such of hands, depth the higher a importantly, and that throughput. unprecedented of via workflow. as probe happening numbers state phenotypes,
This June. X,XXX data presented of Association the called more the and in Proteograph types native ASMS peptides proteins resolution data at upcoming the of open a will versions glycosylated expression detection the identify April, detect enabled hundreds from to PrognomIQ studies. the conference uniquely early At to be than and subjects Suite proteins of analysis Cancer protein We association the in of XXX their of cohort single Research, ongoing also oncology that versions able up were one Proteograph, of their presented Conference demonstrates enabling of a of the across Product researchers to the of In at disease differential glycosylated this simultaneous expect The it American and the experiment. studies progression. same with markets. AACR, in utilizing of scale
sites. to scale studies, more generally fastest as through PrognomIQ While duration. been three customer studies, seeing ramp samples, at to of X,XXX and vary move go steps cohorts ramp they OHSU have of the across with of terms each vary to which in the time can their each we're Customers or
their increase onboard are now. Most their as completed the and release this customers our our the release and Proteograph train First, this initial of staff. they broad have beginning familiarity with process technology, customers limited step they
use perform new insights. answer of questions. specific take they typically to design to their expand finally, biological to studies unlock fine-tune pilot scale And study to those they the studies the technology up Next, to designed their and ramp biological hands-on unprecedented learnings of will
there proteomics all early and less scale-up for also OHSU be more may familiar are protracted. And scale model of the this velocity types While may other workflow. be with scale-up who building at customers We're are customers adopters, of support examples those support of curve. PrognomIQ customers, the to across
and customer types let There's growing a and palpable range wide growing installed Now a across of applications. Product the interest a excitement surrounding Suite Proteograph to turn me our base.
North across continue the have and world. During through of began delivered work broad China, customers COVID where the our quarter, first America, we customers including systems the Europe phase to release now We around and commercialization up and constraints. Asia, first running of three to we
not While our in our these access continue personnel. in ability and temporal quarter in region country prospective of challenge uncertainty constraints introduce China, and for this have own some do did year, first to us material customers, on our a this customers as impact partners the they with restrictions
We the of roughly commercial our equal growing of and academic both continue of mix and pipeline to quality be sites. encouraged by quantity in prospects
pipeline our and bring Suite and grow expand benefits customers. world to Proteograph around to the expect the we more We as Product hiring its our
than toward given be across more their to adopters types, settings, strong customer more to we quickly continue ability expect institutions. academic is interest to move While our weighted early heavily commercial
As data to of process. that third-party still commercialization, its the see in an continue of first important kind early is is of the the technology sales we stages component
to of position These provide I'll in which terms volume rarely typically party been and access of studies, have in grow, proof it time to small While principle size are as depth sample analyze. that data takes but and this data the of size, refer inclined of POPS are undertake are to a a for to customers customers in POPS.
using pleased Proteograph the intend data, interpret imagine Suite. highly is to Product data, the the and what customers possible insights prospective While the with leverage
studies existing in future. adoption sales and less the the POPS data As continue publications, from presentations grows to increase we process expect important curve become customers in and the to via
power As prospective continue technology market, be to base, encouraged and we customer we educate exemplify continue interaction to the customers. to with the by the develop the our of
are we working in addition, following for In Product easier the Suite it Proteograph them the ways. to to make adopt
making one-on-one workflows. integrate First, for them technology the education, providing their simple into specific we're to it
users Second, applications. experienced similar performing we're them connecting with
release an as this for the limited and of collaborators independent early And customers existing customers our that leverage serves important third-party to helping produce purpose. data sites reference finally, technology. to continue we're validation We as
commercial progress. Now moving our to on
As we expand team. we world-class ramp Suite, of our Proteograph commercialization and Product strengthen the continue to
key the our business, passionate top-performing large driving have Seer. attracting team at Our people and in to made is strides we
a our two expanding building over increasing processes we application and products and talented a diverse and infrastructure sciences sales, welcomed product of year this service growth, as chief customer long-term and of such Scott spent talent key thrilled experience As decades XXXX, to In team. industry, field XX executive In expect breadth build Japan, in geographically his market, support, our we expanded officer. of core in years the welcome significantly Scott America, engineers responsibilities complement as had geographies. best as marketing, at run life well He recruiting functions, nicely distributed very organizations team field team a to leadership support globally across has to end help and base. experience us talent, end. commercial Scott building We're and continue accelerate with and our expect mid-March, commercial by including prioritize to and as we and teams, commercial has launching competitive differentiated we commercial global commercial North Europe grow customer scientists, Thomas the to Illumina.
of the the vast Sciences, forward nanoparticles an our Proceedings achieves times a model coverage, Seer The published precision, significant nature interdisciplinary given Let's specific describes X.X much that now from to breakthrough In protein to a confirming in publication the of of its of traditional of and depletion about is Oregon technology's families. throughput and depth technology We're as mid-March, and to what biological as is workflow, unique proud time be enabled of when driven by sample. by of Technology, enhance a Institute sampling and diverse given in simultaneously nanoparticles interface Harvard The identification the between to Medical protein the interrogate Society data median in at several Mass differentially protein pattern paper protein American The the is relationship physical School. design used protein Massachusetts future panel that in the information. such Academy our looking order excited growing was We're pivotal paper presentations this Spectrometry the technology. this paper paper of presentations. of magnitude machine-learning improvement that properties we including this molecular platform detail the deep scientific early University, proprietary-engineered multiple at in to upcoming a team to to molecular to ability conferences. of come higher the panel. a June, nanoparticle unique the move or the We're nano-bio the on in chemical This to gain a Sciences is can PNAS, compared field. interface & surface at occur aperture or customer in Seer, of twice examines year the tunable fractionation. scientists proteomics scientific at interactions the conference National of and that This and between of created sampling nano-bio announced by evidence widen an Health the demonstrates and and proteome seminal reproducible
of a deep prescribed be studies With of the gateway proteomic type up to These limitations capabilities insights the look that will by proteome to data proteome will public, without findings I now the nearly of accessible the at any the David Product labs open their scale turn redefine and to that and to targets. enable be new Proteograph update. experience expanding to will of Suite data of with we call Proteograph becoming Product that, a can methods, deeply demonstration and As customers expands, the interrogating around our the Suite and the gained world. financial the for unique the more third-party forward first-of-its-kind
